What should I do if I become resistant to pemetinib?

Pemetinib is a new type of targeted drug for cholangiocarcinoma. It was initially jointly developed by the American Incyte company and Innovent Biologics and was launched in 2020 Obtained approval from the USFDA in 2018 for the treatment of patients with locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements. It has shown remarkable efficacy in treatment with its unique mechanism of action. However, like many targeted drugs, pemetinib may also face the problem of drug resistance.

When patients develop resistance to pemetinib, doctors can adopt a variety of strategies to deal with it. First, it is important to undergo regular genetic testing to monitor mutations in the FGFR gene. Once new mutations are discovered, doctors may recommend patients switch to other targeted drugs targeting different targets. Different drugs may target different growth signaling pathways of cancer cells, so switching drugs may help re-inhibit cancer cell growth and spread.

Secondly, the use of combination therapy is also an effective method to alleviate drug resistance. By using a variety of drugs with different mechanisms, such as chemotherapy, immunotherapy or other targeted therapies, they can act on multiple signaling pathways for tumor cell survival and growth at the same time, reducing the development of drug resistance. For example, combining pemetinib and immunotherapy may result in better treatment outcomes.

In addition, patients may also consider participating in clinical trials, which may provide new drugs or treatments that may be more effective against drug resistance.

In short, for the problem of pemetinib resistance, doctors will choose the most appropriate response strategy based on the patient's specific situation and resistance mechanism. At the same time, patients also need to pay close attention to their physical condition and changes in illness, and communicate with their doctors in a timely manner so that treatment plans can be adjusted in a timely manner.

xa0

Reference link: https://pmc.ncbi.nlm.nih.gov/articles/PMC9364186/